Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. MU
6. SPY
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'

June 8, 2026 10:48 AM EDT

Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $28.00 price target on Nurix (NASDAQ: NRIX).

The analyst comments "Nurix announced a global collaboration with Roche to co-develop and co-commercialize bex-deg, and in our view this is the outcome investors were hoping... More